Pregnenolone for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Pregnenolone for Health & Longevity

Created on 08/01/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Pregnenolone is a hormone precursor active in the brain. Trials focus on mood, schizophrenia add-on, substance use, and veteran back pain—not healthy-aging studies. Medium-strength signals: bipolar depression benefit and modest pain reduction; cognitive and schizophrenia effects remain mixed or unclear. Short-term use is generally well tolerated, with medium concern for dose-related stimulating and hormone effects. Longevity use remains speculative. (Full Review)

Protocol

Practice pattern A — low-dose hormone/cognitive support (integrative and supplement market)
25–100 mg oral daily
Often morning; not FDA-approved for this use
Practice pattern B — clinical-trial psychiatric/pain adjunct
50–500 mg/day
4–12 weeks as add-on in psychiatric and pain trials
Timing of day
Morning; twice daily if high dose
Half-life ~1–3.5 h; ≤50–100 mg often once daily; higher trial doses frequently divided
Time to effect
Mood (bipolar depression)
4–12 weeks
Trial signals assessed over multi-week add-on courses
Chronic low back pain
4–12 weeks
Pain-diary and recall ratings after fixed escalation protocols
Stress/cue craving
~2 weeks
Laboratory craving/anxiety effects in substance-use studies

Benefits

Contraindications
  • Hormone-sensitive cancers (breast, endometrial, ovarian) or active endometriosis/uterine fibroids
  • Prostate cancer or poorly characterized prostate disease
  • Pregnancy and lactation
  • Children and adolescents
  • Uncontrolled psychiatric illness without clinical oversight when using high doses
    •
Key Interactions
  • Estrogen therapies (estradiol, ethinyl estradiol, conjugated estrogens, many combined oral contraceptives)
  • Progestins and progesterone
  • Testosterone and androgenic agents (including some anabolic products)
  • Other hormone-containing supplements (DHEA, androstenedione, proprietary "hormone support" blends)
  • Sedatives / CNS (central nervous system) depressants (e.g., benzodiazepines such as diazepam, lorazepam; Z-drugs such as zolpidem)
  • Over-the-counter (OTC) sedating products (e.g., diphenhydramine, doxylamine, other first-generation antihistamine sleep aids)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Steroid-like overstimulation and mood activation; androgenic/estrogenic dermatologic and hair effects
    •
  • Low: Gastrointestinal and nonspecific somatic effects; autonomic and sensory symptoms; cardiovascular and sexual-function effects
    •
  • Speculative: Promotion of hormone-sensitive disease; long-term endocrine disruption or HPA-axis adaptation
    •

Monitoring

Marker Target Why
Pregnenolone (serum) Often targeted ~100–200 ng/dL in integrative practice (lab-specific) Confirms absorption and exposure
DHEA-S Age/sex functional mid-range (interpret with lab) Downstream adrenal androgen pathway
Estradiol Sex- and age-appropriate functional range Estrogenic conversion safety
Total / free testosterone Sex-appropriate functional range Androgenic conversion
Progesterone Context-dependent (cycle phase in premenopausal women) Pathway product
Comprehensive metabolic panel Standard clinical optimal Liver/kidney safety context
Complete blood count (if androgenic symptoms or co-androgens) Standard clinical Androgen-related high red-cell mass risk context

Cadence: Baseline before sustained use; 4–8 weeks after initiation or dose change; then every 3–6 months if continued

Qualitative Assessment

  • Sleep onset/maintenance and next-day activation or irritability
  • Mood stability (including any hypomanic edge (elevated or irritable mood short of full mania))
  • Skin (acne), hair (shedding or unwanted growth)
  • Pain scores if pain is a target
  • Subjective cognitive clarity and working memory in daily tasks—tracked cautiously given mixed trial cognition data
  • Energy without restlessness or overstimulation
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.